Quid Pro Quo transactions or “Quids” are deals in which licensees offset the cost of an alliance by offering a non-cash asset in place of increased cash payment or another drug. The majority of these deals tend to involve a small biotech company with a late-stage drug to offer and a large pharmaceutical company gaining access to the drug, although it is not exclusively the case. This article discusses Quids in relation to the incentives they hold for both the parties involved and also the limitations of such types of agreements.